Infection barriers to successful xenotransplantation focusing on porcine endogenous retroviruses

Clinical Microbiology Reviews

Volumn 25, Issue 2, 2012, Pages 318-343

  Denner, Joachim ^a   Tönjes, Ralf R ^b  

^a ROBERT KOCH INSTITUTE   (Germany)

^b PAUL EHRLICH INSTITUT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 1; CYCLOSPORIN; DIDANOSINE; EVEROLIMUS; METHYLPREDNISOLONE; PHYTOHEMAGGLUTININ; VIRUS PROTEIN; VIRUS RNA; ZIDOVUDINE;

ACUTE VASCULAR REJECTION; ALLOGRAFT; BLOOD VISCOSITY; CANCER CELL CULTURE; CELL CULTURE; CIRCOVIRUS; DIABETES MELLITUS; DONOR; EBOLA VIRUS; ELECTRON MICROSCOPY; EPILEPSY; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROENTERITIS; GENE LOCUS; GLOMERULONEPHRITIS; HEMORRHAGIC FEVER; HUMAN IMMUNODEFICIENCY VIRUS 1; HUNTINGTON CHOREA; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; IN VITRO STUDY; IN VIVO STUDY; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; LYMPH NODE; LYMPHOMA CELL; MARBURG VIRUS; MELANOMA; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PARKINSON DISEASE; PROTEIN EXPRESSION; PROVIRUS; RETROVIRUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RNA INTERFERENCE; SCANNING ELECTRON MICROSCOPY; STRUCTURAL GENE; TRANSMISSION ELECTRON MICROSCOPY; VIRUS PARTICLE; WESTERN BLOTTING; XENOTRANSPLANTATION;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ENDOGENOUS RETROVIRUSES; HUMANS; RETROVIRIDAE INFECTIONS; SWINE; TRANSPLANTATION, HETEROLOGOUS;

ANIMALIA; PORCINE ENDOGENOUS RETROVIRUS; SUIDAE; SUS;

EID: 84859555709     PISSN: 08938512     EISSN: 10986618     Source Type: Journal    
DOI: 10.1128/CMR.05011-11     Document Type: Review

References (363)

1. Abouna GM. 1997. Extracorporeal xenogenic liver perfusion for the treatment of hepatic failure, p 785-792. In Cooper DKC, Kemp E, Platt JL, White DJG (ed), Xenotransplantation. Springer, Berlin, Germany.
2. Abrahante JE, et al. 2011. Microbiological safety of porcine islets: comparison with source pig. Xenotransplantation 18:88-93.
3. Akiyoshi DE, et al. 1998. Identification of a full-length cDNA for an endogenous retrovirus of miniature swine. J. Virol. 72:4503-4507.
4. Anderson M. 2006. Xenotransplantation: a bioethical evaluation. J. Med. Ethics 32:205-208.
5. Andersson AC, et al. 2002. Developmental expression of HERV-R (ERV3) and HERV-K in human tissue. Virology 297:220-225.
6. Argaw T, Colon-Moran W, Wilson CA. 2004. Limited infection without evidence of replication by porcine endogenous retrovirus in guinea pigs. J. Gen. Virol. 85:15-19.
7. Argaw T, Ritzhaupt A, Wilson CA. 2002. Development of a real time quantitative PCR assay for detection of porcine endogenous retrovirus. J. Virol. Methods 106:97-106.
8. Argaw T, Figueroa M, Salomon DR, Wilson CA. 2008. Identification of residues outside of the receptor binding domain that influence the infectivity and tropism of porcine endogenous retrovirus. J. Virol. 82:7483-7491.
9. Armstrong JA, Porterfield JS, De Madrid A. 1971. C-type virus particles in pig kidney cell lines. J. Gen. Virol. 10:195-198.
10. Athas GB, Choi B, Prabhu S, Lobelle-Rich PA, Levy LS. 1995. Genetic determinants of feline leukemia virus-induced multicentric lymphomas. Virology 214:431-438.
11. Athas GB, Lobelle-Rich P, Levy LS. 1995. Function of a unique sequence motif in the long terminal repeat of feline leukemia virus isolated from an unusual set of naturally occurring tumors. J. Virol. 69:3324-3332.
12. Barrette RW, et al. 2009. Discovery of swine as a host for the Reston ebolavirus. Science 325:204-206.
13. Bartosch B, et al. 2004. Evidence and consequence of porcine endogenous retrovirus recombination. J. Virol. 78:13880-13890.
14. Bauer A, et al. 2010. First experience with heterotopic thoracic pig-tobaboon cardiac xenotransplantation. Xenotransplantation 17:243-249.
15. Beckwith J, Nyman JA, Flanagan B, Schrover R, Schuurman H-J. 2010. A health-economic analysis of porcine islet xenotransplantation. Xenotransplantation 17:233-242.
16. Benveniste RE, Todaro GJ. 1973. Homology between type-C viruses of various species as determined by molecular hybridization. Proc. Natl. Acad. Sci. U. S. A. 70:3316-3320.
17. Bishop KN, Holmes RK, Malim MH. 2006. Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J. Virol. 80:8450-8458.
18. Bishop KN, et al. 2004. Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr. Biol. 14:1392-1396.
19. Bloom ET. 2001. New FDA xenotransplantation documents: a proposed rule and a draft guidance. Xenotransplantation 8:153-154.
20. Bloom ET. 2001. Xenotransplantation: regulatory challenges. Curr. Opin. Biotechnol. 12:312-316.
21. Blusch JH, et al. 2000. Infection of nonhuman primate cells by pig endogenous retrovirus. J. Virol. 74:7687-7690.
22. Blusch JH, Roos C, Nitschko H. 2000. A polymerase chain reactionbased protocol for the detection of transmission of pig endogenous retroviruses in pig to human xenotransplantation. Transplantation 69: 2167-2172.
23. Bogerd HP, Tallmadge RL, Oaks JL, Carpenter S, Cullen BR. 2008. Equine infectious anemia virus resists the antiretroviral activity of equine APOBEC3 proteins through a packaging-independent mechanism. J. Virol. 82:11889-11901.
24. Bösch S, Arnauld C, Jestin A. 2000. Study of full-length porcine endogenous retrovirus genomes with envelope gene polymorphism in a specific-pathogen-free Large White swine herd. J. Virol. 74:8575-8581.
25. Bouilant AMP, Grieg AS, Lieber MM, Todaro GJ. 1975. Type-C virus production by a continuous line of pig oviduct cells (PFT). J. Gen. Virol. 27:173-180.
26. Bowden TR, Westenberg M, Wang LF, Eaton BT, Boyle DB. 2001. Molecular characterization of Menangle virus, a novel paramyxovirus which infects pigs, fruit bats, and humans. Virology 283:358-373.
27. Breese SS, Jr. 1970. Virus-like particles occurring in cultures of stable pig kidney cell lines. Arch. Gesamte Virusforsch. 30:401-404.
28. Breimer ME, et al. 1998. Extracorporeal ("ex vivo") connection of pig kidneys to dialyses patients. I. Clinical data and studies on platelet destruction. Xenotransplantation 3:328-335.
29. Browne EP, Littman DR. 2008. Species-specific restriction of apobec 3-mediated hypermutation. J. Virol. 82:1305-1313.
30. Buhler L, et al. 2000. Coagulation and thrombotic disorders associated with pig organ and hematopoietic cell transplantation in nonhuman primates. Transplantation 70:1323-1331.
31. Büscher K, et al. 2006. Expression of the human endogenous retrovirus-K transmembrane envelope, Rec and Np9 proteins in melanomas and melanoma cell lines. Melanoma Res. 16:223-234.
32. Büscher K, et al. 2005. Expression of human endogenous retrovirus K in melanomas and melanoma cell lines. Cancer Res. 65:4172-4180.
33. Byrne G, McCurry K, Martin M, Platt J, Logan J. 1996. Development and analysis of transgenic pigs expressing the human complement regulatory protein CD59 and DAF. Transplant. Proc. 28:759.
34. Cantu E, et al. 2007. Prolonged function of macrophage, von Willebrand factor-deficient porcine pulmonary xenografts. Am. J. Transplant. 7:66-75.
35. Ceglowski WS, Friedman H. 1968. Immunosuppression by leukemia viruses. I. Effect of Friend disease virus on cellular and humoral hemolysin responses of mice to a primary immunization with sheep erythrocytes. J. Immunol. 101:594-604.
36. Chen RH, Mitchell RN, Kadner A, Adams DH. 1999. Differential galactose alpha(1,3) galactose expression by porcine cardiac vascular endothelium. Xenotransplantation 6:169-172.
37. Chen RH, Naficy S, Logan JS, Diamond LE, Adams DH. 1999. Hearts from transgenic pigs constructed with CD59/DAF genomic clones demonstrate improved survival in primates. Xenotransplantation 6:194-200.
38. Chen D, et al. 2004. Complete inhibition of acute humoral rejection using regulated expression of membrane-tethered anticoagulants on xenograft endothelium. Am. J. Transplant. 4:1958-1963.
39. Chmielewicz B, et al. 2003. A novel porcine gammaherpesvirus. Virology 308:317-329.
40. Chmielewicz B, Goltz M, Lahrmann KH, Ehlers B. 2003. Approaching virus safety in xenotransplantation: a search for unrecognized herpesviruses in pigs. Xenotransplantation 10:349-356.
41. Choi KM, et al. Production of transgenic cloned miniature pigs with membrane- bound human Fas ligand (FasL) by somatic cell nuclear transfer. Nat. Precedings, in press. http://precedings.nature.com/documents/4539/version/1/files/npre20104539_1.pdf.
42. Chua KB, et al. 1999. Fatal encephalitis due to Nipah virus among pig-farmers in Malaysia. Lancet 354:1257-1259.
43. Chua KW, et al. 2001. Tioman virus, a novel paramyxovirus isolated from fruit bats in Malaysia. Virology 283:215-222.
44. Cianciolo G, Copeland T, Oroszlan S, Snyderman R. 1985. Inhibition of lymphocyte proliferation by a synthetic peptide homologous to retroviral envelope proteins. Science 230:453-455.
45. Clark MA. 1999. This little piggy went to market: the xenotransplantation and xenozoonose debate. J. Law Med. Ethics 27:137-152.
46. Clemenceau B, Lalain S, Martignat L, Sai P. 1999. Porcine endogenous retroviral mRNAs in pancreas and a panel of tissues from specific pathogen-free pigs. Diabetes Metab. 25:518-525.
47. Clémenceau B, Jégou D, Martignat L, Saï P. 2002. Microchimerism and transmission of porcine endogenous retrovirus from a pig cell line or specific pathogen-free pig islets to mouse tissues and human cells during xenografts in nude mice. Diabetologia 45:914-923.
48. Conticello SG, Thomas CJ, Petersen-Mahrt SK, Neuberger MS. 2005. Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases. Mol. Biol. Evol. 22:367-377.
49. Cooper DK. 1998. Xenoantigens and xenoantibodies. Xenotransplantation 5:6-17.
50. Cooper DK, Koren E, Oriol R. 1994. Clinical potential of xenotransplantation. Transplant. Proc. 26:1331-1332.
51. Cooper DK, Koren E, Oriol R. 1994. Oligosaccharides and discordant xenotransplantation. Immunol. Rev. 141:31-58.
52. Cornetta K, et al. 1990. Amphotropic murine leukemia retrovirus is not an acute pathogen for primates. Hum. Gene Ther. 1:15-30.
53. Costa C, et al. 1999. Expression of the human alpha1,2-fucosyltransferase in transgenic pigs modifies the cell surface carbohydrate phenotype and confers resistance to human serum-mediated cytolysis. FASEB J. 13:1762-1773.
54. Costa C, et al. 2002. Transgenic pigs designed to express human CD59 and H-transferase to avoid humoral xenograft rejection. Xenotransplantation 9:45-57.
55. Cowan PJ, et al. 2000. Renal xenografts from triple-transgenic pigs are not hyperacutely rejected but cause coagulopathy in nonimmunosuppressed baboons. Transplantation 69:2504-2515.
56. Cowan PJ, et al. 2003. Targeting gene expression to endothelium in transgenic animals: a comparison of the human ICAM-2, PECAM-1 and endoglin promoters. Xenotransplantation 10:223-231.
57. Cozzi E, White DJ. 1995. The generation of transgenic pigs as potential organ donors for humans. Nat. Med. 1:964-966.
58. Cunningham D, et al. 1999. Expression of porcine endogenous retroviruses in hDAF transgenic pigs, abstr A1154. 5th Cong. Int. Xenotransplant. Assoc., Nagoya, Japan.
59. Czaplicki J, Blońska B, Religa Z. 1992. The lack of hyperacute xenogeneic heart transplant rejection in a human. J. Heart Lung Transplant. 11:393-397.
60. Czauderna F, Fischer N, Boller K, Kurth R, Tönjes RR. 2000. Establishment and characterisation of molecular clones of porcine endogenous retroviruses replicating on human cells. J. Virol. 74:4028-4038.
61. Dai Y, et al. 2002. Targeted disruption of the alpha1,3-galactosyltransferase gene in cloned pigs. Nat. Biotechnol. 20:251-255.
62. Danaei G, et al. 2011. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 378:31-40. doi:10.1016/S0140-6736(11)60679-X.
63. Deng YM, Tuch BE, Rawlinson WD. 2000. Transmission of porcine endogenous retroviruses in severe combined immunodeficient mice xenotransplanted with fetal porcine pancreatic cells. Transplantation 70: 1010-1016.
64. Denner J. 1987. Immunosuppression by oncogenic Retroviridae, p 114-201. In Zschiesche W (ed), Immune modulation by infectious agents. Fischer Verlag, Jena, Germany.
65. Denner J. 1998. Immunosuppression by retroviruses: implications for xenotransplantation. Ann. N. Y. Acad. Sci. 862:75-86.
66. Denner J. 2000. How does HIV induce AIDS? The virus protein hypothesis J. Hum. Virol. 3:81-82.
67. Denner J. 2003. Porcine endogenous retroviruses (PERVs) and xenotransplantation: screening for transmission in several clinical trials and in experimental models using non-human primates. Ann. Transplant. 8:39-48.
68. Denner J. 2007. Transspecies transmissions of retroviruses: new cases. Virology 369:229-233.
69. Denner J. 2008. Xenotransplantation: state of the art of biosafety, p 7-79. In Jansen ES, Simon JW (ed), Xenotransplantationethic, economic, social, cultural and scientific background, vol 1. VDM-Verlag, Saarbrücken, Germany.
70. Denner J. 2008. Recombinant porcine endogenous retroviruses (PERVA/C): a new risk for xenotransplantation? Arch. Virol. 153:1421-1426.
71. Denner J. 2010. Endogenous retroviruses, p 35-69. In Kurth R, Bannert N (ed), Retroviruses: molecular biology, genomics and pathogenesis. Caister Academic Press, Hethersett, Norwich, United Kingdom.
72. Denner J. 2010. Detection of a gammaretrovirus, XMRV, in the human population: open questions and implications for xenotransplantation. Retrovirology 7:16.
73. Denner J. 2011. Towards an AIDS vaccine: the transmembrane envelope protein as target for broadly neutralising antibodies. Hum. Vaccines 7(Suppl):4-9.
74. Denner J. 2011. Infectious risk in xenotransplantation-what posttransplant screening for the human recipient? Xenotransplantation 18: 151-157.
75. Denner J, Behrendt R, Kurth R. 2005. Modulation of cytokine production by the transmembrane envelope protein gp41 of HIV-1. Retrovirology 2:153.
76. Denner J, Norley S, Kurth R. 1994. The immunosuppressive peptide of HIV-1: functional domains and immune response in AIDS patients. AIDS 8:1063-1072.
77. Denner J, et al. 1996. The immunosuppressive peptide of HIV-1 inhibits T and B lymphocyte stimulation. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 12:442-450.
78. Denner J, Schuurman H, Patience C. 2009. The International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes. Chapter 5. Strategies to prevent transmission of porcine endogenous retroviruses. Xenotransplantation 16:239-248.
79. Denner J, Phelps RC, Löwer J, Löwer R, Kurth R. 1995. Expression of the human endogenous retrovirus HERV-K in tumor and normal tissues and antibody response of pregnant women, tumor and AIDS patients against HERV-K GAG and ENV peptides. AIDS Res. Hum. Retroviruses 11:156.
80. Denner J, et al. 2008. No transmission of porcine endogenous retroviruses (PERVs) in a long-term pig to rat xenotransplantation model and no infection of immunosuppressed rats. Ann. Transplant. 13:20-31.
81. Denner J, Specke V, Thiesen U, Karlas A, Kurth R. 2003. Genetic alterations of the long terminal repeat of an ecotropic porcine endogenous retrovirus during passage in human cells. Virology 314:125-133.
82. DesGroseillers L, Jolicoeur P. 1984. The tandem direct repeats within the long terminal repeat of murine leukemia viruses are the primary determinant of their leukemogenic potential. J. Virol. 52:945-952.
83. Diamond LE, et al. 1996. Characterization of transgenic pigs expressing functionally active human CD59 on cardiac endothelium. Transplantation 61:1241-1249.
84. Diamond LE, et al. 2001. A human CD46 transgenic pig model system for the study of discordant xenotransplantation. Transplantation 71: 132-142.
85. Dieckhoff B, et al. 2007. Inhibition of porcine endogenous retroviruses (PERVs) in primary porcine cells by RNA interference using lentiviral vectors. Arch. Virol. 152:629-634.
86. Dieckhoff B, et al. 2009. Distribution and expression of porcine endogenous retroviruses in multi-transgenic pigs generated for xenotransplantation. Xenotransplantation 16:64-73.
87. Dieckhoff B, et al. 2008. Knockdown of porcine endogenous retrovirus (PERV) expression by PERV-specific shRNA in transgenic pigs. Xenotransplantation 15:36-45.
88. Dieckhoff B, et al. 2007. Expression of porcine endogenous retroviruses (PERVs) in melanomas of Munich miniature swine (MMS) Troll. Vet. Microbiol. 123:53-68.
89. Di Nicuolo G, et al. 2010. Long-term absence of porcine endogenous retrovirus infection in chronically immunosuppressed patients after treatment with the porcine cell-based Academic Medical Center bioartificial liver. Xenotransplantation 17:431-439.
90. Di Nicuolo G, et al. 2005. No evidence of in vitro and in vivo porcine endogenous retrovirus infection after plasmapheresis through the AMCbioartificial liver. Xenotransplantation 12:286-292.
91. Dinsmore JH, Manhart C, Raineri R, Jacoby DB, Moore A. 2000. No evidence for infection of human cells with porcine endogenous retrovirus (PERV) after exposure to porcine fetal neuronal cells. Transplantation 70:1382-1389.
92. Dörrschuck E, et al. 2011. Restriction of porcine endogenous retrovirus by porcine APOBEC3 cytidine deaminases. J. Virol. 85:3842-3857.
93. Dörrschuck E, Münk C, Tönjes RR. 2008. APOBEC3 proteins and porcine endogenous retroviruses. Transplant. Proc. 40:959-961.
94. Echard G. 1974. Chromosomal banding patterns and karyotype evolution in three pig kidney cell strains (PK15, F and RP). Chromosoma 45:133-149.
95. Ehlers B, Ulrich S, Goltz M. 1999. Detection of two novel porcine herpesviruses with high similarity to gammaherpesviruses. J. Gen. Virol. 80:971-978.
96. Ekser B, et al. 2012. Clinical xenotransplantation-the next medical revolution? Lancet 379:672-683.
97. Elliott RB, et al. 2000. No evidence of infection with porcine endogenous retrovirus in recipients of encapsulated porcine islet xenografts. Cell Transplant. 9:895-901.
98. EMA (European Medicines Agency). 22 October 2009, posting date. Guideline on xenogeneic cell-based medicinal products. EMEA/CHMP/CPWP/83508/2009. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/12/WC500016936.pdf.
99. Ericsson T, et al. 2001. Identification of novel porcine endogenous betaretrovirus sequences in miniature swine. J. Virol. 75:2765-2770.
100. Ericsson TA, et al. 2003. Identification of receptors for pig endogenous retrovirus. Proc. Natl. Acad. Sci. U. S. A. 100:6759-6764.
101. FDA/PHS. 19 January 2001, posting date. Guideline on infectious disease issues in xenotransplantation. http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Xenotransplantation/ucm074727.htm.
102. Fiebig U, Hartmann MG, Bannert N, Kurth R, Denner J. 2006. Transspecies transmission of the endogenous koala retrovirus (KoRV). J. Virol. 80:5651-5654.
103. Fiebig U, Stephan O, Kurth R, Denner J. 2003. Neutralizing antibodies against conserved domains of p15E of porcine endogenous retroviruses (PERVs): basis for a vaccine for xenotransplantation? Virology 307:406-413.
104. Fink JS, et al. 2000. Porcine xenografts in Parkinson's disease and Huntington's disease patients: preliminary results. Cell Transplant. 9:273-278.
105. Finsterbusch T, Mankertz A. 2009. Porcine circoviruses-small but powerful. Virus Res. 143:177-183.
106. Fischer N, Krach U, Niebert M, Tönjes RR. 2003. Detection of porcine endogenous retrovirus (PERV) using highly specific antisera against Gag and Env. Virology 311:222-228.
107. Fishman JA. 1994. Miniature swine as organ donor for man: strategies for prevention of xenotransplant-associated infections. Xenotransplantation 1:47-57.
108. Fishman JA. 2001. Infection in xenotransplantation. J. Card. Surg. 16: 363-373.
109. Fishman JA, Patience C. 2004. Xenotransplantation: infectious risk revisited. Am. J. Transplant. 4:1383-1390.
110. Fodor WL, et al. 1994. Expression of a functional human complement inhibitor in a transgenic pig as a model for the prevention of xenogeneic hyperacute organ rejection. Proc. Natl. Acad. Sci. U. S. A. 91:11153-11157.
111. Frazier ME. 1985. Evidence for retrovirus in miniature swine with radiation-induced leukemia or metaplasia. Arch. Virol. 83:83-97.
112. Frühauf JH, Mertsching H, Giri S, Frühauf NR, Bader A. 2009. Porcine endogenous retrovirus released by a bioartificial liver infects primary human cells. Liver Int. 29:1553-1561.
113. Furuta RA, et al. 2011. No association of xenotropic murine leukemia virus-related virus with prostate cancer or chronic fatigue syndrome in Japan. Retrovirology 8:20.
114. Galbraith DN, et al. 2000. Design and validation of immunological tests for the detection of porcine endogenous retrovirus in biological materials. J. Virol. Methods 90:115-124.
115. Garkavenko O, et al. 2008. Absence of transmission of potentially xenotic viruses in a prospective pig to primate islet xenotransplantation study. J. Med. Virol. 80:2046-2052.
116. Garkavenko O, et al. 2004. Monitoring for presence of potentially xenotic viruses in recipients of pig islet xenotransplantation. J. Clin. Microbiol. 42:5353-5356.
117. Garkavenko O, et al. 2008. Porcine endogenous retrovirus transmission characteristics from a designated pathogen-free herd. Transplant. Proc. 40:590-593.
118. Gemeniano M, Mpanju O, Salomon DR, Eiden MV, Wilson CA. 2006. The infectivity and host range of the ecotropic porcine endogenous retrovirus, PERV-C, is modulated by residues in the C-terminal region of its surface envelope protein. Virology 346:108-117.
119. Goff SP. 2004. HIV: replication trimmed back. Nature 427:791-793.
120. Goff SP. 2004. Retrovirus restriction factors. Mol. Cell 16:849-859.
121. Hahn BH, Shaw GM, De Cock KM, Sharp PM. 2000. AIDS as a zoonosis: scientific and public health implications. Science 287:607-614.
122. Hammer C. 1997. Evolutionary obstacles to xenotransplantation, p 716-735. In Cooper DKC, Kemp E, Platt JL, White DJG (ed), Xenotransplantation, 2nd ed. Springer, Heidelberg, Germany.
123. Hara H, et al. 2011. Initial in vitro investigation of the human immune response to corneal cells from genetically engineered pigs. Invest. Ophthalmol. Vis. Sci. 52:5278-5286.
124. Haraguchi S, Good R, Day N. 1995. Immunosuppressive retroviral peptides: cAMP and cytokine patterns. Immunol. Today 16:595-603.
125. Harris RS, et al. 2003. DNA deamination mediates innate immunity to retroviral infection. Cell 113:803-809.
126. Harris RS, Liddament MT. 2004. Retroviral restriction by APOBEC proteins. Nat. Rev. Immunol. 4:868-877.
127. Harrison I, Takeuchi Y, Bartosch B, Stoye JP. 2004. Determinants of high titer in recombinant porcine endogenous retroviruses. J. Virol. 78: 13871-13879.
128. Heidmann T, Heidmann O, Nicolas JF. 1987. An indicator gene to demonstrate intracellular transposition of defective retroviruses. Proc. Natl. Acad. Sci. U. S. A. 85:2219-2223.
129. Heneine W. 1996. Strategies for diagnosis of xenotransplant-associated retroviral infections. Mol. Diagn. 1:255-260.
130. Heneine W, et al. 1998. No evidence of infection with porcine endogenous retrovirus in recipients of porcine islet-cell xenografts. Lancet 352: 695-699.
131. Heneine W, et al. 2001. Evidence of porcine endogenous retroviruses in porcine factor VIII and evaluation of transmission to recipients with hemophilia. J. Infect. Dis. 183:648-652.
132. Hering BJ, et al. 2009. The International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes- executive summary. Xenotransplantation 16:196-202.
133. Hermida-Prieto M, et al. 2007. Lack of cross-species transmission of porcine endogenous retrovirus (PERV) to transplant recipients and abattoir workers in contact with pigs. Transplantation 84:548-550.
134. Herring C, et al. 2001. Mapping full-length porcine endogenous retroviruses in a Large White pig. J. Virol. 75:12252-12265.
135. Hirst MW, Felton A. 2008. The UN Resolution on Diabetes and World Diabetes Day. Prim. Care Diabetes 2:95-96.
136. Hofmann-Lehmann R, et al. 2007. Vaccination against the feline leukaemia virus: outcome and response categories and long-term followup. Vaccine 25:5531-5539.
137. Hohn O, et al. 2009. Lack of evidence for XMRV in prostate cancer biopsies from German patients. Retrovirology 6:92.
138. Holmes RK, Koning FA, Bishop KN, Malim MH. 2007. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. J. Biol. Chem. 282:2587-2595.
139. Holmes RK, Malim MH, Bishop KN. 2007. APOBEC-mediated viral restriction: not simply editing? Trends Biochem. Sci. 32:118-128.
140. Hué S, et al. 2010. Disease-associated XMRV sequences are consistent with laboratory contamination. Retrovirology 7:111.
141. Ierino FL, et al. 1998. Disseminated intravascular coagulation in association with the delayed rejection of pig-to-baboon renal xenografts. Transplantation 66:1439-1450.
142. Irgang M, et al. 2005. Porcine endogenous retroviruses PERV-A and PERV-B infect neither mouse cells in vitro nor SCID mice in vivo. Intervirology 48:167-173.
143. Irgang M, et al. 2008. No evidence for PERV release by islet cells from German landrace pigs. Ann. Transplant. 13:59-66.
144. Irgang M, et al. 2003. Porcine endogenous retroviruses: no infection in patients treated with a bioreactor based on porcine liver cells. J. Clin. Virol. 28:141-154.
145. Iwatani Y, et al. 2007. Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res. 35:7096-7108.
146. Jarmuz A, et al. 2002. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 79:285-296.
147. Jern P, Stoye JP, Coffin JM. 2007. Role of APOBEC3 in genetic diversity among endogenous murine leukemia viruses. PLoS Genet. 3:2014-2022.
148. Jonsson SR, et al. 2006. Evolutionarily conserved and non-conserved retrovirus restriction activities of artiodactyl APOBEC3F proteins. Nucleic Acids Res. 34:5683-5694.
149. Jonsson SR, et al. 2007. The restriction of zoonotic PERV transmission by human APOBEC3G. PLoS One 2:e893.
150. Jung WY, et al. 2010. Comparison of PERV genomic locations between Asian and European pigs. Anim. Genet. 41:89-92.
151. Jungmann A, Tönjes RR. 2008. Retrotransposition: another obstacle for xenotransplantation? Transplant. Proc. 40:596-597.
152. Kaiser J. 2011. Chronic fatigue syndrome. Studies point to possible contamination in XMRV findings. Science 331:17.
153. Karlas A, et al. 2010. Characterisation of a human cell-adapted porcine endogenous retrovirus PERV-A/C. Ann. Transplant. 15:45-54.
154. Karlas A, Kurth R, Denner J. 2004. Inhibition of porcine endogenous retroviruses byRNAinterference: increasing the safety of xenotransplantation. Virology 325:18-23.
155. Katopodis AG, et al. 2002. Removal of anti-Gala1,3Gal xenoantibodies with an injectable polymer. J. Clin. Invest. 110:1869-1877.
156. Kaulitz D, et al. 2011. Generation of neutralising antibodies against porcine endogenous retroviruses (PERVs). Virology 411:78-86.
157. Kaulitz D, et al. 2011. Absence of infection in pigs inoculated with high-titre recombinant PERV-A/C. Arch. Virol. 156:707-710.
158. Kaulitz D, et al. 2011. Development of sensitive methods for detection of porcine endogenous retrovirus-C (PERV-C) in the genome of pigs. J. Virol. Methods 175:60-65.
159. Klose R, et al. 2005. Expression of biologically active human TRAIL in transgenic pigs. Transplantation 80:222-230.
160. Klymiuk N, Aigner B, Brem G, Wolf E. 2010. Genetic modification of pigs as organ donors for xenotransplantation. Mol. Reprod. Dev. 77: 209-221.
161. Kobayashi M, et al. 2004. APOBEC3G targets specific virus species. J. Virol. 78:8238-8244.
162. Krach U, Fischer N, Czauderna F, Kurth R, Tönjes RR. 2000. Generation and testing of a highly specific anti-serum directed against porcine endogenous retrovirus nucleocapsid. Xenotransplantation 7:221-229.
163. Krach U, Fischer N, Czauderna F, Tönjes RR. 2001. Comparison of replication-competent molecular clones of porcine endogenous retrovirus class A and class B derived from pig and human cells. J. Virol. 75: 5465-5472.
164. Kuddus RH, et al. 2004. Porcine cell microchimerism but lack of productive porcine endogenous retrovirus (PERV) infection in naive and humanized SCID-beige mice treated with porcine peripheral blood mononuclear cells. Transpl. Immunol. 13:15-24.
165. Kuddus R, et al. 2002. Clinical and laboratory evaluation of the safety of a bioartificial liver assist device for potential transmission of porcine endogenous retrovirus. Transplantation 73:420-429.
166. Kuwaki K, et al. 2005. Heart transplantation in baboons using alpha1,3-galactosyltransferase gene-knockout pigs as donors: initial experience. Nat. Med. 11:29-31.
167. Lai L, et al. 2002. Production of alpha-1,3-galactosyltransferase knockout pigs by nuclear transfer cloning. Science 295:1089-1092.
168. Langford GA, et al. 2001. In vivo analysis of porcine endogenous retrovirus expression in transgenic pigs. Transplantation 72:1996-2000.
169. Langhammer S, Fiebig U, Kurth R, Denner J. 2011. Increased neutralizing antibody response after simultaneous immunization with leucogen and the feline leukemia virus transmembrane protein. Intervirology 54: 78-86.
170. Langhammer S, Fiebig U, Kurth R, Denner J. 2005. Neutralising antibodies against the transmembrane protein of feline leukaemia virus (FeLV). Vaccine 23:3341-3348.
171. Langhammer S, Hübner J, Jarrett O, Kurth R, Denner J. 2011. Immunization with the transmembrane protein of a retrovirus, feline leukemia virus: absence of antigenemia following challenge. Antiviral Res. 89:119-123.
172. Langhammer S, Hübner J, Kurth R, Denner J. 2005. Antibodies neutralising feline leukemia virus (FeLV) in cats immunised with the transmembrane envelope protein p15E. Immunology 117:229-237.
173. Langlois MA, Kemmerich K, Rada C, Neuberger MS. 2009. The AKV murine leukemia virus is restricted and hypermutated by mouse APOBEC3. J. Virol. 83:11550-11559.
174. Larue RS, et al. 2008. The artiodactyl APOBEC3 innate immune repertoire shows evidence for a multi-functional domain organization that existed in the ancestor of placental mammals. BMC Mol. Biol. 9:104.
175. Larue RS, et al. 2009. Guidelines for naming nonprimate APOBEC3 genes and proteins. J. Virol. 83:494-497.
176. Lavillette D, Kabat D. 2004. Porcine endogenous retroviruses infect cells lacking cognate receptors by an alternative pathway: implications for retrovirus evolution and xenotransplantation. J. Virol. 78:8868-8877.
177. Lecossier D, Bouchonnet F, Clavel F, Hance AJ. 2003. Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 300:1112.
178. Lee J, et al. 2011. Repression of porcine endogenous retrovirus infection by human APOBEC3 proteins. Biochem. Biophys. Res. Commun. 407: 266-270.
179. Lee JC, Ihle JN, Huebner R. 1977. The humoral immune response of NIH Swiss and SWR/J mice to vaccination with formalinized AKR or Gross murine leukemia virus. Proc. Natl. Acad. Sci. U. S. A. 74:343-347.
180. Lee JH, Webb GC, Allen RD, Moran C. 2002. Characterizing and mapping porcine endogenous retroviruses in Westran pigs. J. Virol. 76: 5548-5556.
181. Le Tissier P, Stoye JP, Takeuchi Y, Patience C, Weiss RA. 1997. Two sets of human-tropic pig retrovirus. Nature 389:681-682.
182. Levy MF, et al. 2000. Liver allotransplantation after extracorporeal hepatic support with transgenic (hCD55/hCD59) porcine livers: clinical results and lack of pig-to-human transmission of the porcine endogenous retrovirus. Transplantation 69:272-280.
183. Li M, Xu F, Muller J, Hearing VJ, Gorelik E. 1998. Ecotropic C-type retrovirus of B16 melanoma and malignant transformation of normal melanocytes. Int. J. Cancer 76:430-436.
184. Lieber MM, Sherr CJ, Benveniste RE, Todaro GJ. 1975. Biologic and immunologic properties of porcine type C virus. Virology 66:616.
185. Löchelt M, et al. 2005. The antiretroviral activity of APOBEC3 is inhibited by the foamy virus accessory Bet protein. Proc. Natl. Acad. Sci. U. S. A. 102:7982-7987.
186. Loss M, et al. 2001. Analysis of potential porcine endogenous retrovirus (PERV) transmission in a whole-organ xenotransplantation model without interfering microchimerism. Transpl. Int. 14:31-37.
187. Low A, et al. 2009. Enhanced replication and pathogenesis of Moloney murine leukemia virus in mice defective in the murine APOBEC3 gene. Virology 385:455-463.
188. Ma Y, et al. 2010. Real-time quantitative polymerase chain reaction with SYBR green I detection for estimating copy numbers of porcine endogenous retrovirus from Chinese miniature pigs. Transplant. Proc. 42: 1949-1952.
189. Makowka L, Cramer DV, Hoffman A. 1995. The use of a pig xenograft for temporary support of a patient with fulminant hepatic failure. Transplantation 59:1654-1659.
190. Mangeat B, et al. 2003. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424:99-103.
191. Marcucci KT, Martina Y, Harrison F, Wilson CA, Salomon DR. 2008. Functional hierarchy of two L domains in porcine endogenous retrovirus (PERV) that influence release and infectivity. Virology 375:637-645.
192. Marcucci KT, Argaw T, Wilson CA, Salomon DR. 2009. Identification of two distinct structural regions in a human porcine endogenous retrovirus receptor, HuPAR2, contributing to function for viral entry. Retrovirology 6:3.
193. Mariani R, et al. 2003. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114:21-31.
194. Marin M, Rose KM, Kozak SL, Kabat D. 2003. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat. Med. 9:1398-1403.
195. Martin U, et al. 1998. Expression of pig endogenous retrovirus by primary porcine endothelial cells and infection of human cells. Lancet 352: 692-694.
196. Martin U, et al. 1998. Porcine endogenous retrovirus (PERV) was not transmitted from transplanted porcine endothelial cells to baboons in vivo. Transpl. Int. 11:247-251.
197. Martin SI, Wilkinson R, Fishman JA. 2006. Genomic presence of recombinant porcine endogenous retrovirus in transmitting miniature swine. J. Virol. 3:91-96.
198. Martina Y, et al. 2005. Pseudotyping of porcine endogenous retrovirus by xenotropic murine leukemia virus in a pig islet xenotransplantation model. Am. J. Transplant. 5:1837-1847.
199. Martina Y, et al. 2006. Mice transgenic for a human porcine endogenous retrovirus receptor are susceptible to productive viral infection. J. Virol. 80:3135-3146. (Erratum, 80:5100.)
200. Mathes L, et al. 1979. Immunosuppressive properties of a virion polypeptide, a 15,000-dalton protein, from feline leukemia virus. Cancer Res. 39:950-955.
201. Matthews AL, et al. 1999. Development and validation of a Western immunoblot assay for detection of antibodies to porcine endogenous retrovirus. Transplantation 67:939-943.
202. Mattiuzzo G, Takeuchi Y. 2010. Suboptimal porcine endogenous retrovirus infection in non-human primate cells: implication for preclinical xenotransplantation. PLoS One 5:e13203.
203. Mattiuzzo G, Matouskova M, Takeuchi Y. 2007. Differential resistance to cell entry by porcine endogenous retrovirus subgroup A in rodent species. Retrovirology 4:93.
204. Mattiuzzo G, Ivol S, Takeuchi Y. 2010. Regulation of porcine endogenous retrovirus release by porcine and human tetherins. J. Virol. 84: 2618-2622.
205. Mbisa JL, et al. 2007. Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J. Virol. 81:7099-7110.
206. McKane BW, Ramachandran S, Yang J, Xu XC, Mohanakumar T. 2003. Xenoreactive anti-Galalpha(1,3)Gal antibodies prevent porcine endogenous retrovirus infection of human in vivo. Hum. Immunol. 64: 708-717.
207. McKane BW, et al. 2004. Natural antibodies prevent in vivo transmission of porcine islet-derived endogenous retrovirus to human cells. Cell Transplant. 13:137-143.
208. McKeown NE, Fenaux M, Halbur PG, Meng XJ. 2004. Molecular characterization of porcine TT virus, an orphan virus, in pigs from six different countries. Vet. Microbiol. 104:113-117.
209. Medina RA, GarcíA-Sastre A. 2011. Influenza A viruses: new research developments. Nat. Rev. Microbiol. 9:590-603.
210. Meije Y, Tönjes RR, Fishman JA. 2010. Retroviral restriction factors and infectious risk in xenotransplantation. Am. J. Transplant. 10:1511-1516.
211. Mendoza R, Vaughan AE, Miller AD. 2011. The left half of the XMRV retrovirus is present in an endogenous retrovirus of NIH/3T3 Swiss mouse cells. J. Virol. 85:9247-9248.
212. Meng XJ. 2003. Swine hepatitis E virus: cross-species infection and risk in xenotransplantation. Curr. Top. Microbiol. Immunol. 278:185-216.
213. Meng XJ, et al. 1997. A novel virus in swine is closely related to the human hepatitis E virus. Proc. Natl. Acad. Sci. U. S. A. 94:9860-9865.
214. Millard AL, Mueller NJ. 2010. Can human viruses infect porcine xenografts? Xenotransplantation 17:6-10.
215. Millard AL, et al. 2010. Efficiency of porcine endothelial cell infection with human cytomegalovirus depends on both virus tropism and endothelial cell vascular origin. Xenotransplantation 17:274-287.
216. Miyagawa S, et al. Remodeling of the major pig xenoantigen by Nacetylglucosaminyltransferase III in transgenic pig. J. Biol. Chem. 276: 39310-39319.
217. Moennig V, et al. 1974. C-type particles produced by a permanent cell line from a leukemic pig. II. Physical, chemical and serological characterization of the particles. Virology 57:179-188.
218. Moscoso I, et al. 2005. Lack of cross-species transmission of porcine endogenous retrovirus in pig-to-baboon xenotransplantation with sustained depletion of anti-alphagal antibodies. Transplantation 79:777-782.
219. Mueller NJ, et al. 2005. Early weaning of piglets fails to exclude porcine lymphotropic herpesvirus. Xenotransplantation 12:59-62.
220. Mullon C, Pitkin Z. 1999. The HepatAssist bioartificial liver support system: clinical study and pig hepatocyte process. Expert Opin. Invest. Drugs 8:229-235.
221. Münk C, et al. 2008. Functions, structure, and read-through alternative splicing of feline APOBEC3 genes. Genome Biol. 9:R48.
222. Muster T, et al. 2003. An endogenous retrovirus derived from human melanoma cells. Cancer Res. 63:8735-8741.
223. Newman EN, et al. 2005. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr. Biol. 15:166-170.
224. Nguyen BH, Zwets E, Schroeder C, Pierson RN III, Azimzadeh AM. 2005. Beyond antibody-mediated rejection: hyperacute lung rejection as a paradigm for dysregulated inflammation. Curr. Drug Targets Cardiovasc. Haematol. Disord. 5:255-269.
225. Niebert M, Kurth R, Tönjes RR. 2003. Retroviral safety: analyses of phylogeny, prevalence and polymorphisms of porcine endogenous retroviruses. Ann. Transplant. 8:56-64.
226. Niebert M, Tönjes RR. 2003. Analyses of prevalence and polymorphisms of six replication-competent and chromosomally assigned porcine endogenous retroviruses in individual pigs and pig subspecies. Virology 313:427-434.
227. Niebert M, Rogel-Gaillard C, Chardon P, Tönjes RR. 2002. Characterization of chromosomally assigned replication-competent gamma porcine endogenous retroviruses derived from a Large White pig and expression in human cells. J. Virol. 76:2714-2720.
228. Niemann H. 2001. Current status and perspectives for the generation of transgenic pigs for xenotransplantation. Ann. Transplant. 6:6-9.
229. Niemann H, et al. 2001. Cytomegalovirus early promoter induced expression of hCD59 in porcine organs provides protection against hyperacute rejection. Transplantation 72:1898-1906.
230. Nishitai R, et al. 2005. Absence of PERV infection in baboons after transgenic porcine liver perfusion. J. Surg. Res. 124:45-51.
231. O'Dair HA, Hopper CD, Gruffydd-Jones TJ, Harbour DA, Waters L. 1994. Clinical aspects of Chlamydia psittaci infection in cats infected with feline immunodeficiency virus. Vet. Rec. 134:365-368.
232. OECD/WHO. 26 October 2001. OECD/WHO consultation on xenotransplantation surveillance: summary. http://whqlibdoc.who.int/hq/2001/WHO_CDS_CSR_EPH_2001.1.pdf.
233. OhAinle M, Kerns JA, Malik HS, Emerman M. 2006. Adaptive evolution and antiviral activity of the conserved mammalian cytidine deaminase APOBEC3H. J. Virol. 80:3853-3862.
234. Okura E, et al. 2008. Differential human serum-mediated neutralization of PERV released from pig cells transfected with variants of hDAF. Xenotransplantation 15:365-373.
235. Oldmixon BA, et al. 2002. Porcine endogenous retrovirus transmission characteristics of an inbred herd of miniature swine. J. Virol. 76:3045-3048.
236. Onions D, et al. 2000. An approach to the control of disease transmission in pig-to-human xenotransplantation. Xenotransplantation 7:143-155.
237. Oostendorp RA, Meijer CJ, Scheper RJ. 1993. Immunosuppression by retroviral-envelope-related proteins, and their role in non-retroviral human disease. Crit. Rev. Oncol. Hematol. 14:189-206.
238. Oropeza M, et al. 2009. Transgenic expression of the human A20 gene in cloned pigs provides protection against apoptotic and inflammatory stimuli. Xenotransplantation 16:522-534.
239. Overbaugh J, Miller AD, Eiden MV. 2001. Receptors and entry cofactors for retroviruses include single and multiple transmembranespanning proteins as well as newly described glycophosphatidylinositolanchored and secreted proteins. Microbiol. Mol. Biol. Rev. 65:371-389.
240. Pal N, et al. 2011. Detection of porcine endogenous retrovirus (PERV) viremia in diseased versus healthy US pigs by qualitative and quantitative real-time RT-PCR. Transbound. Emerg. Dis. 58:344-351. doi:10.1111/j.1865-1682.2011.01210.x.
241. Paprotka T, et al. 2011. Recombinant origin of the retrovirus XMRV. Science 333:97-101.
242. Paradis K, et al. 1999. Search for cross-species transmission of porcine endogenous retrovirus in patients treated with living pig tissue. Science 285:1236-1241.
243. Park JS, et al. 2005. Birth abnormalities in pregnant sows infected intranasally with porcine circovirus 2. J. Comp. Pathol. 132:139-144.
244. Patience C, Takeuchi Y, Weiss RA. 1997. Infection of human cells by an endogenous retrovirus of pigs. Nat. Med. 3:282-286.
245. Patience C, et al. 1998. No evidence of pig DNA or retroviral infection in patients with short-term extracorporeal connection to pig kidneys. Lancet 352:699-701.
246. Patience C, et al. 2001. Multiple groups of novel retroviral genomes in pigs and related species. J. Virol. 75:2771-2775.
247. Perkovic M, et al. 2009. Species-specific inhibition of APOBEC3C by the prototype foamy virus protein bet. J. Biol. Chem. 284:5819-5826.
248. Petersen B, Carnwath JW, Niemann H. 2009. The perspectives for porcine-to-human xenografts. Comp. Immunol. Microbiol. Infect. Dis. 32:91-105.
249. Petersen B, et al. 2009. Pigs transgenic for human thrombomodulin have elevated production of activated protein C. Xenotransplantation 16:486-495.
250. Petersen B, et al. 2010. Generation and characterization of pigs transgenic for human hemeoxygenase-1 (hHO-1). Xenotransplantation 17: 102-103.
251. Phelps CJ, et al. 2009. Production and characterization of transgenic pigs expressing porcine CTLA4-Ig. Xenotransplantation 16:477-485.
252. Phelps CJ, et al. 2003. Production of alpha1,3-galactosyltransferase deficient pigs. Science 299:411-414.
253. Pierson RN, et al. 2009. Current status of xenotransplantation and prospects for clinical application. Xenotransplantation 16:263-280.
254. Pitkin Z, Mullon C. 1999. Evidence of absence of porcine endogenous retrovirus (PERV) infection in patients treated with a bioartificial liver support system. Artif. Organs 23:829-833.
255. Powell SK, et al. 2000. Antiretroviral agents inhibit infection of human cells by porcine endogenous retroviruses. Antimicrob. Agents Chemother. 44:3432-3433.
256. Preuss T, Fischer N, Boller K, Tönjes RR. 2006. Isolation and characterization of an infectious replication-competent molecular clone of ecotropic porcine endogenous retrovirus class C. J. Virol. 80:10258-10261.
257. Qari SH, et al. 2001. Susceptibility of the porcine endogenous retrovirus to reverse transcriptase and protease inhibitors. J. Virol. 75:1048-1053.
258. Quinn G, et al. 2004. Porcine endogenous retrovirus transmission characteristics of galactose alpha1-3 galactose-deficient pig cells. J. Virol. 78: 5805-5811.
259. Quinn G, et al. 2004. Genotyping of porcine endogenous retroviruses from a family of miniature swine. J. Virol. 78:314-319.
260. Ramackers W, et al. 2008. Effects of pharmacological intervention on coagulopathy and organ function in xenoperfused kidneys. Xenotransplantation 15:46-55.
261. Ramsoondar J, et al. 2009. Production of transgenic pigs that express porcine endogenous retrovirus small interfering RNAs. Xenotransplantation 16:164-180.
262. Redpath S, Ghazal P, Gascoigne NR. 2001. Hijacking and exploitation of IL-10 by intracellular pathogens. Trends Microbiol. 9:86-92.
263. Reemtsma K. 1969. Renal transplantation from non-human primates to man. Ann. N. Y. Acad. Sci. 162:412-418.
264. Ritzhaupt A, Van Der Laan LJ, Salomon DR, Wilson CA. 2002. Porcine endogenous retrovirus infects but does not replicate in nonhuman primate primary cells and cell lines. J. Virol. 76:11312-11320.
265. Rogel-Gaillard C, Bourgeaux N, Billault A, Vaiman M, Chardon P. 1999. Construction of a swine BAC library: application to the characterization and mapping of porcine type C endoviral elements. Cytogenet. Cell Genet. 85:205-211.
266. Rogel-Gaillard C, Hayes H, Bourgeaux N, Chardon P. 2001. Assignment of two new loci for gamma 1 porcine endogenous retroviruses (gamma 1 PERV) to pig chromosome bands 2q21 and 11q12 by in situ hybridization. Cytogenet. Cell Genet. 95:112-113.
267. Rosengard AM, et al. 1995. Endothelial expression of human decay accelerating factor in transgenic pig tissue: a potential approach for human complement inactivation in discordant xenografts. Transplant. Proc. 27:326-327.
268. Ross SR. 2009. Are viruses inhibited by APOBEC3 molecules from their host species? PLoS Pathog. 5:e1000347.
269. Ruegg C, Monell C, Strand M. 1989. Identification, using synthetic peptides, of the minimum amino acid sequence from the retroviral transmembrane protein p15E required for inhibition of lymphoproliferation and its similarity to gp21 of human T-lymphotropic virus types I and II. J. Virol. 63:3250-3256.
270. Ruegg C, Monell C, Strand M. 1989. Inhibition of lymphoproliferation by a synthetic peptide with sequence identity to gp41 of human immunodeficiecy virus type 1. J. Virol. 63:3257-3260.
271. Russell RA, et al. 2005. Foamy virus Bet proteins function as novel inhibitors of the APOBEC3 family of innate antiretroviral defense factors. J. Virol. 79:8724-8731.
272. Sandström H, et al. 1973. C-type particles produced by a permanent cell line from a leukemic pig. I. Origin and properties of the host cells and some evidence for the occurrence of C-type-like particles. Virology 57: 175-178.
273. Santiago ML, et al. 2008. Apobec3 encodes Rfv3, a gene influencing neutralizing antibody control of retrovirus infection. Science 321:1343-1346.
274. Santoni F, et al. 2006. Molecular interactions between porcine and human gammaherpesviruses: implications for xenografts? Xenotransplantation 13:308-317.
275. Sato E, Furuta RA, Miyazawa T. 2010. An endogenous murine leukemia viral genome contaminant in a commercial RT-PCR kit is amplified using standard primers for XMRV. Retrovirology 7:110.
276. Sauer M, et al. 2003. Clinical extracorporeal hybrid liver support-phase I study with primary porcine liver cells. Xenotransplantation 10: 460-469.
277. Sayre KR, et al. 1996. False-positive human immunodeficiency virus type 1 Western blot tests in noninfected blood donors. Transfusion 36: 45-52.
278. Scheef G, Fischer N, Krach U, Tönjes R. 2001. The number of a U3 repeat box acting as an enhancer in long terminal repeats of polytropic replication-competent porcine endogenous retroviruses dynamically fluctuates during serial virus passages in human cells. J. Virol. 75:6933-6940.
279. Scheef G, Fischer N, Flory E, Schmitt I, Tönjes RR. 2002. Transcriptional regulation of porcine endogenous retroviruses released from porcine and infected human cells by heterotrimeric protein complex NF-Y and impact of immunosuppressive drugs. J. Virol. 76:12553-12563.
280. Schlecht-Louf G, et al. 2010. Retroviral infection in vivo requires an immune escape virulence factor encrypted in the envelope protein of oncoretroviruses. Proc. Natl. Acad. Sci. U. S. A. 107:3782-3787.
281. Schmoeckel M, et al. 1998. Orthotopic heart transplantation in a transgenic pig-to-primate model. Transplantation 6:1570-1577.
282. Schumacher JM, et al. 2000. Transplantation of embryonic porcine mesencephalic tissue in patients with PD. Neurology 54:1042-1050.
283. Schuurman H-J, Pierson RN III. 2008. Progress towards clinical xenotransplantation. Front. Biosci. 13:204-220.
284. Schuurman HJ. 2009. The International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes. Chapter 2. Source pigs. Xenotransplantation 16:215-222.
285. Schuurman H-J. 2011. Xenotransplantation: from the lab to the clinic: Sunrise Symposium at the XXIII International Congress of the Transplantation Society, Vancouver, Canada. Clin. Transpl. 25:E415-E421. doi:10.1111/j.1399-0012.2011.01471.x.
286. Scobie L, Takeuchi Y. 2009. Porcine endogenous retrovirus and other viruses in xenotransplantation. Curr. Opin. Organ Transplant. 14:175-179.
287. Scobie L, et al. 2004. Characterization of germline porcine endogenous retroviruses from Large White pig. J. Gen. Virol. 85:2421-2428.
288. Scobie L, et al. 2004. Absence of replication-competent human-tropic porcine endogenous retroviruses in the germ line DNA of inbred miniature swine. J. Virol. 78:2502-2509.
289. Seifarth W, et al. 2003. Assessment of retroviral activity using a universal retrovirus chip. J. Virol. Methods 112:79-91.
290. Sheehy AM, Gaddis NC, Malim MH. 2003. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 9:1404-1407.
291. Sheehy AM, Gaddis NC, Choi JD, Malim MH. 2002. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418:646-650.
292. Shin CH, et al. 2011. Absence of XMRV retrovirus and other murine leukemia virus-related viruses in patients with chronic fatigue syndrome. J. Virol. 85:7195-7202.
293. Simon AR, et al. 2003. No evidence for productive PERV infection of baboon cells in in vivo infection model. Ann. Transplant. 8:24-34.
294. Smith RA. 2010. Contamination of clinical specimens with MLVencoding nucleic acids: implications for XMRV and other candidate human retroviruses. Retrovirology 7:112.
295. Specke V, Tacke S, Boller K, Schwendemann J, Denner J. 2001. Porcine endogenous retroviruses (PERVs): in vitro host range and attempts to establish small animal models. J. Gen. Virol. 82:837-844.
296. Specke V, Rubant S, Denner J. 2001. Productive infection of human primary cells and cell lines with porcine endogenous retroviruses (PERVs). Virology 285:177-180.
297. Specke V, et al. 2002. Virus safety in xenotransplantation: preliminary data from first small animal and non-human primate in vivo experiments. Transplant. Immunol. 9:281-288.
298. Specke V, Plesker R, Coulibaly C, Boller K, Denner J. 2002. Productive infection of a mink cell line with porcine endogenous retroviruses (PERVs) and lack of transmission to minks in vivo. Arch. Virol. 147:305-319.
299. Specke V, et al. 2009. No in vivo infection of triple immunosuppressed non-human primates after inoculation with high titers of porcine endogenous retroviruses. Xenotransplantation 16:34-44.
300. Stephan O, et al. 2001. Porcine endogenous retroviruses (PERVs): generation of specific antibodies, development of an immunoperoxidase assay (IPA) and inhibition by AZT. Xenotransplantation 8:310-316.
301. Stoye JP, Coffin JM. 1995. The dangers of xenotransplantation. Nat. Med. 1:1100.
302. Stoye JP, Moroni C, Coffin JM. 1991. Virological events leading to spontaneous AKR thymomas. J. Virol. 65:1273-1285.
303. Suling K, Quinn G, Wood J, Patience C. 2003. Packaging of human endogenous retrovirus sequences is undetectable in porcine endogenous retrovirus particles produced from human cells. Virology 312:330-336.
304. Suzuka I, Sekiguchi K, Kodama M. 1985. Some characteristics of a porcine retrovirus from a cell line derived from swine malignant lymphomas. FEBS Lett. 183:124-128.
305. Suzuka I, et al. 1986. Molecular cloning of unintegrated closed circular DNA of porcine retrovirus. FEBS Lett. 198:339-343.
306. Swindle MM. 1998. Defining appropriate health status and management programs for specific-pathogen-free swine for xenotransplantation. Ann. N. Y. Acad. Sci. 862:111-120.
307. Switzer WM, et al. 2001. Lack of cross-species transmission of porcine endogenous retrovirus infection to nonhuman primate recipients of porcine cells, tissues, or organs. Transplantation 71:959-965.
308. Switzer WM, Shanmugam V, Chapman L, Heneine W. 1999. Polymerase chain reaction assays for the diagnosis of infection with the porcine endogenous retrovirus and the detection of pig cells in human and nonhuman recipients of pig xenografts. Transplantation 68:183-188.
309. Sykes M, d'Apice A, Sandrin M. 2004. Position paper of the Ethics Committee of the International Xenotransplantation Association. Transplantation 78:1101-1107.
310. Tacke S, Bodusch K, Berg A, Denner J. 2001. Sensitive and specific detection methods for porcine endogenous retroviruses applicable to experimental and clinical xenotransplantation. Xenotransplantation 8:125-135.
311. Tacke S, Kurth R, Denner J. 2000. Porcine endogenous retrovirus inhibits human immune cells: risk for xenotransplantation. Virology 268:87-93.
312. Tacke SJ, Specke V, Denner J. 2003. Differences in release and determination of subtype of porcine endogenous retroviruses produced by stimulated normal pig blood cells. Intervirology 46:17-24.
313. Takeda E, et al. 2008. Mouse APOBEC3 restricts Friend leukemia virus infection and pathogenesis in vivo. J. Virol. 82:10998-11008.
314. Takefman DM, Spear GT, Saifuddin M, Wilson CA. 2002. Human CD59 incorporation into porcine endogenous retrovirus particles: implications for the use of transgenic pigs for xenotransplantation. J. Virol. 76:1999-2002.
315. Takefman DM, Wong S, Maudru T, Peden K, Wilson CA. 2001. Detection and characterization of porcine endogenous retrovirus in porcine plasma and porcine factor VIII. J. Virol. 75:4551.
316. Takeuchi Y, et al. 1998. Host range and interference studies of three classes of pig endogenous retrovirus. J. Virol. 72:9986-9991.
317. Tarlinton RE, Meers J, Young PR. 2006. Retroviral invasion of the koala genome. Nature 442:79-81.
318. Tarlinton R, Meers J, Young P. 2008. Biology and evolution of the endogenous koala retrovirus. Cell. Mol. Life Sci. 65:3413-3421.
319. Tchenio T, Heidmann T. 1991. Defective retroviruses can disperse in the human genome by intracellular transposition. J. Virol. 65:2113-2118.
320. Tchenio T, Heidmann T. 1992. High-frequency intracellular transposition of a defective mammalian provirus detected by an in situ colorimetric assay. J. Virol. 66:1571-1578.
321. Thein E, Hammer C. 2004. Physiologic barriers to xenotransplantation. Curr. Opin. Organ Transplant. 9:186-189.
322. Tibell A, Groth C. 1998. No viral disease after xenotransplantation. Nature 392:646.
323. Todaro GJR, Benveniste RE, Lieber MM, Sherr CJ. 1974. Characteri-sation of a type C virus released from the porcine cell line PK(15). Virology 58:65-74.
324. Tönjes RR, Czauderna F, Kurth R. 1999. Genome-wide screening, cloning, chromosomal assignment, and expression of full-length human endogenous retrovirus type K. J. Virol. 73:9187-9195.
325. Tönjes RR, et al. 1996. HERV-K: the biologically most active human endogenous retrovirus family. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1:261-267.
326. Torres AN, O'Halloran KP, Larson LJ, Schultz RD, Hoover EA. 2010. Feline leukemia virus immunity induced by whole inactivated virus vaccination. Vet. Immunol. Immunopathol. 134:122-131.
327. Tucker A, et al. 2002. The production of transgenic pigs for potential use in clinical xenotransplantation: microbiological evaluation. Xenotransplantation 9:191-202.
328. Tucker AW, et al. 2003. Methods for the exclusion of circoviruses and gammaherpesviruses from pigs. Xenotransplantation 10:343-348.
329. Tulsiani SM, et al. 2011. Emerging tropical diseases in Australia. Part 5. Hendra virus. Ann. Trop. Med. Parasitol. 105:1-11.
330. Van der Laan LJ, et al. 2000. Infection by porcine endogenous retrovirus after islet xenotransplantation in SCID mice. Nature 407:90-94.
331. Van der Pool HY. 1999. Commentary: a critique of Clark's frightening xenotransplantation scenario. J. Law Med. Ethics 27:153-157.
332. Van der Pool HY. 1999. Xenotransplantation: progress and promise. West. J. Med. 171:333-335.
333. Voevodin AF, et al. 1997. Phylogenetic analysis of simian T-lymphotropic virus type I (STLV-I) in common chimpanzees (Pan troglodytes): evidence for interspecies transmission of the virus between chimpanzees and humans in Central Africa. Virology 238:212-220.
334. Wanke R, Bein J, Ring J, Hermanns W. 1998. Munich miniature swine Troll (UM-line): a porcine model of hereditary cutaneous melanoma. J. Invest. Dermatol. 110:722.
335. Watanabe T, Watanabe S, Kawaoka Y. 2010. Cellular networks involved in the influenza virus life cycle. Cell Host Microbe 7:427-439.
336. Weiss EH, et al. 2009. HLA-E/human beta2-microglobulin transgenic pigs: protection against xenogeneic human anti-pig natural killer cell cytotoxicity. Transplantation 87:35-43.
337. Whitteker JL, Dudani AK, Tackeberry ES. 2008. Human fibroblasts are permissive for porcine cytomegalovirus in vitro. Transplantation 86: 155-162.
338. Wilson CA. 2008. Porcine endogenous retroviruses and xenotransplantation. Cell. Mol. Life Sci. 65:3399-3412.
339. Wilson CA, et al. 1998. Type C retrovirus released from porcine primary peripheral blood mononuclear cells infects human cells. J. Virol. 72: 3082-3087.
340. Wilson CA, Laeeq S, Ritzhaupt A, Colon-Moran W, Yoshimura FK. 2003. Sequence analysis of porcine endogenous retrovirus long terminal repeats and identification of transcriptional regulatory regions. J. Virol. 77:142-149.
341. Wilson CA, Wong S, Van Brocklin M, Federspiel MJ. 2000. Extended analysis of the in vitro tropism of porcine endogenous retrovirus. J. Virol. 74:49-56.
342. Winkler ME, et al. 2005. Analysis of pig-to-human porcine endogenous retrovirus transmission in a triple-species kidney xenotransplantation model. Transpl. Int. 17:848-858.
343. Wolf D, Goff SP. 2008. Host restriction factors blocking retroviral replication. Annu. Rev. Genet. 42:143-163.
344. Wood et al. 2009. Porcine endogenous retroviruses PERV A and A/C recombinant are insensitive to a range of divergent mammalian TRIM5alpha proteins including human TRIM5alpha. J. Gen. Virol. 90: 702-709.
345. Wood JC, et al. 2004. Identification of exogenous forms of humantropic porcine endogenous retrovirus in miniature swine. J. Virol. 78: 2494-2501.
346. Woods WA, Papas TS, Hirumi H, Chirigos MA. 1973. Antigenic and biochemical characterisation of the C-type particle of the stable porcine kidney cell line PK-15. J. Virol. 12:1184-1186.
347. Wynyard S, Garkavenko O, Elliot R. 2011. Multiplex high resolution melting assay for estimation of porcine endogenous retrovirus (PERV) relative gene dosage in pigs and detection of PERV infection in xenograft recipients. J. Virol. Methods 175:95-100.
348. Xia H, Wahlberg N, Belák S, Meng XJ, Liu L. 2011. The emergence of genotypes 3 and 4 hepatitis E virus in swine and humans: a phylogenetic perspective. Arch. Virol. 156:121-124.
349. Xu H, et al. 2003. Serologic analysis of anti-porcine endogenous retroviruses immune responses in humans after ex vivo transgenic pig liver perfusion. ASAIO J. 49:407-416.
350. Yaiw KC, et al. 2008. Tioman virus, a paramyxovirus of bat origin, causes mild disease in pigs and has a predilection for lymphoid tissues. J. Virol. 82:565-568.
351. Yamada K, et al. 2005. Marked prolongation of porcine renal xenograft survival in baboons through the use of alpha1,3-galactosyltransferase gene-knockout donors and the cotransplantation of vascularized thymic tissue. Nat. Med. 11:32-34.
352. Yamashita T, et al. 1991. Isolation of cytopathic small round viruses with BS-C-1 cells from patients with gastroenteritis. J. Infect. Dis. 164: 954-957.
353. Yang YG, et al. 2004. Mouse retrovirus mediates porcine endogenous retrovirus transmission into human cells in long-term human-porcine chimeric mice. J. Clin. Invest. 114:695-700.
354. Yang Y-G, Sykes M. 2007. Xenotransplantation: current status and a perspective on the future. Nat. Rev. 7:519-531.
355. Yazaki S, et al. 2009. Successful cross-breeding of cloned pigs expressing endo-beta-galactosidase C and human decay accelerating factor. Xenotransplantation 16:511-521.
356. Yu JM, et al. 2011. Analysis and characterization of the complete genome of a member of a new species of kobuvirus associated with swine. Arch. Virol. 156:747-751.
357. Yu Y, Xiao Z, Ehrlich ES, Yu X, Yu XF. 2004. Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev. 18:2867-2872.
358. Yu X, et al. 2003. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302:1056-1060.
359. Zaidi A, et al. 1998. Life-supporting pig-to-primate renal xenotransplantation using genetically modified donors. Transplantation 65:1584-1590.
360. Zhang H, et al. 2003. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424:94-98.
361. Zhang W, et al. 2008. The first Chinese porcine sapovirus strain that contributed to an outbreak of gastroenteritis in piglets. J. Virol. 82:8239-8240.
362. Zhou CY, et al. 2005. Transgenic pigs expressing human CD59, in combination with human membrane cofactor protein and human decay-accelerating factor. Xenotransplantation 12:142-148.
363. Zielonka J, et al. 2009. Restriction of equine infectious anemia virus by equine APOBEC3 cytidine deaminases. J. Virol. 83:7547-7559.